|  |  |  |  |  |
| Company | Aladdin Scientific Corporation | Aladdin Scientific Corporation | Aladdin Scientific Corporation | Aladdin Scientific Corporation | Aladdin Scientific Corporation |
| Item | ESF1 Human Pre-designed siRNA Set A | Amyloid β-Protein Fragment 25-35 | IRE1α kinase-IN-2 | LightNing™ EagI | SHP2 protein degrader-2 |
| Catalog Number | E1469574 | A107853 | I648023 | L397162 | S648891 |
| Price | Supplier Page | Supplier Page | Supplier Page | Supplier Page | Supplier Page |
| Quantity | 1Set | 100mg, 5mg, 2mg, 1mg, 25mg | 100mg, 5mg, 50mg, 10mg, 25mg | 1kit | 50mg, 10mg, 100mg, 5mg, 25mg, 1mg |
| Type | Bioactive Small Molecules | Chelating Agents & Ligands | Chelating Agents & Ligands | Proteins | Chelating Agents & Ligands |
| Description | ESF1 Human Pre-designed siRNA Set A contains three designed siRNAs for ESF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components ESF1 siRNA-1: 5 nmol (HPLC) ESF1 siRNA-2: 5 nmol (HPLC) ESF1 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 ESF1 Human Pre-designed siRNA Set A contains three designed siRNAs for ESF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components ESF1 siRNA-1: 5 nmol (HPLC) ESF1 siRNA-2: 5 nmol (HPLC) ESF1 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Amyloid β-Protein Fragment 25-35 (Aβ25-35) is derived from the amyloid-β protein.amyloid-β protein, which is mapped to human chromosome 21q21.Aβ25-35 lacks the N-terminal domain and the metal binding site and is majorly generated by proteolytic cleavage of Aβ(1−40Amyloid β-Protein Fragment 25-35 (Aβ25-35) is derived from the amyloid-β protein.amyloid-β protein, which is mapped to human chromosome 21q21.Aβ25-35 lacks the N-terminal domain and the metal binding site and is majorly generated by proteolytic cleavage of Aβ(1−40) peptides. It has a β-sheet and β-turn structure. Amino Acid Sequence Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-MetFunctional domain of Aβ required for both neurotrophic and neurotoxic effects... Read More | IRE1α kinase-IN-2 is a potent IRE1α kinase inhibitor, with an EC 50 of 0.82 µM. IRE1α kinase-IN-2 inhibits IRE1α kinase autophosphorylation (IC 50 =3.12 µM). IRE1α kinase-IN-2 inhibits XBP1 mRNA splicing in the WT cell lines.In VitroIRE1α kinase-IN-2 (compoundIRE1α kinase-IN-2 is a potent IRE1α kinase inhibitor, with an EC 50 of 0.82 µM. IRE1α kinase-IN-2 inhibits IRE1α kinase autophosphorylation (IC 50 =3.12 µM). IRE1α kinase-IN-2 inhibits XBP1 mRNA splicing in the WT cell lines.In VitroIRE1α kinase-IN-2 (compound 3) inhibits XBP1 mRNA splicing, even during ER stress. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:Solid... Read More | Inquire | SHP2 protein degrader-2 (SHP2-D26) is a SHP2 protein PROTAC degrader. SHP2 protein degrader-2 reduces expression level of SHP2 in various cancer cells.In VitroSHP2 protein degrader-2 (SHP2-D26) achieves excellent degradation of SHP2 with the DC 50 (the concentration where 50% of the protein has beenSHP2 protein degrader-2 (SHP2-D26) is a SHP2 protein PROTAC degrader. SHP2 protein degrader-2 reduces expression level of SHP2 in various cancer cells.In VitroSHP2 protein degrader-2 (SHP2-D26) achieves excellent degradation of SHP2 with the DC 50 (the concentration where 50% of the protein has been degraded) values of 2.6 nM and 6.0 nM for MV4;11 and KYSE520 cells, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:Solid... Read More |
| Get Quote | Supplier Page | Supplier Page | Supplier Page | Supplier Page | Supplier Page |